Bio-Works has confirmed a new order for a customized, prepacked solution worth SEK 0.8 million to be used in a viral vector manufacturing process. The initial order is for process validation runs, and the potential annual revenue from the project is estimated to be between SEK 3-12 million. The customer is an American contract manufacturer of gene therapy products.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.28 SEK | -2.98% | -16.48% | -67.89% |
May. 17 | Sweden's Bio-Works Technologies Recruits New CEO | MT |
May. 17 | Bio-Works Technologies AB Announces Executive Changes | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-67.89% | 8.56M | |
-4.77% | 179B | |
+4.10% | 113B | |
-3.85% | 67.88B | |
+5.19% | 52.03B | |
+5.54% | 43.3B | |
+6.27% | 41.79B | |
+23.81% | 32.49B | |
+15.88% | 25.65B | |
-5.06% | 24.55B |
- Stock Market
- Equities
- BIOWKS Stock
- News Bio-Works Technologies AB
- Bio-Works Secures SEK 0.8 Million Order for Gene Therapy Manufacturing